183 related articles for article (PubMed ID: 33609315)
1. Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; Boluda B; Rodríguez-Veiga R; Cano I; Acuña-Cruz E; Blanco A; Marco-Ayala J; de la Puerta R; Díaz-González Á; Piñana JL; Sanz J; Sempere A; Cervera J; Barragán E; Sargas C; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Eur J Haematol; 2021 May; 106(5):724-733. PubMed ID: 33609315
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.
Griffin JD; Yang H; Song Y; Kinrich D; Shah MV; Bui CN
Eur J Haematol; 2019 Apr; 102(4):341-350. PubMed ID: 30578743
[TBL] [Abstract][Full Text] [Related]
3. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.
Dombret H; Thomas X; Chevallier P; Nivot E; Reitan J; Barber B; Barlev A; Mohty M
J Med Econ; 2016 Nov; 19(11):1034-1039. PubMed ID: 27207188
[TBL] [Abstract][Full Text] [Related]
4. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
Kabra M; Margotto L; Manuguid F
Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study.
Solana-Altabella A; Megías-Vericat JE; Ballesta-López O; Boluda B; Cano I; Acuña-Cruz E; Rodríguez-Veiga R; Torres-Miñana L; Sargas C; Sanz MÁ; Borrell-García C; López-Briz E; Poveda-Andrés JL; De la Rubia J; Montesinos P; Martínez-Cuadrón D
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454828
[TBL] [Abstract][Full Text] [Related]
7. Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain.
Boluda B; Rodríguez-Veiga R; Martínez-Cuadrón D; Lorenzo I; Sanz J; Regadera A; Sempere A; Senent L; Cervera JV; Solves P; Reitan J; Gea S; Sanz MA; Montesinos P
Pharmacoecon Open; 2019 Jun; 3(2):229-235. PubMed ID: 30324566
[TBL] [Abstract][Full Text] [Related]
8. Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; Martínez-Cuadrón D; Algarra L; Cano I; Sayas MJ; Acuña-Cruz E; Blanco A; Marco-Ayala J; DeLapuerta R; Díaz-González Á; Tormo M; Rodríguez-Veiga R; García R; Piñana JL; López-Pavía M; Barragán E; Amigo ML; Sargas C; López A; Solana-Altabella A; Gil C; Megías-Vericat JE; Sanz MA; Montesinos P
Leuk Lymphoma; 2021 Nov; 62(11):2727-2736. PubMed ID: 34121593
[TBL] [Abstract][Full Text] [Related]
9. French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.
Garnham A; Bruon F; Berthon C; Lebon D; Parimi M; Polya R; Makhloufi KM; Dramard-Goasdoue MH
Oncol Ther; 2023 Sep; 11(3):375-389. PubMed ID: 37578642
[TBL] [Abstract][Full Text] [Related]
10. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract][Full Text] [Related]
12. Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.
Maertens J; Graux C; Breems D; Havelange V; Wittnebel S; Strens D; Hoefkens C
Acta Clin Belg; 2017 Dec; 72(6):429-433. PubMed ID: 28406385
[TBL] [Abstract][Full Text] [Related]
13. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
[TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
[TBL] [Abstract][Full Text] [Related]
15. Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.
Pandya BJ; Chen CC; McGuiness CB; Sullivan L; Feng Q; Walsh E; Borate U
Expert Rev Hematol; 2022 Sep; 15(9):857-866. PubMed ID: 35924860
[TBL] [Abstract][Full Text] [Related]
16. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
18. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
[TBL] [Abstract][Full Text] [Related]
19. [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Zhang Y; Xuan L; Fan Z; Huang F; Jiang Q; Xu N; Gao Y; Sun J; Liu Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):292-6. PubMed ID: 27093991
[TBL] [Abstract][Full Text] [Related]
20. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
